Rory J Mccrimmon

List of Publications by Year
in descending order

152 papers	11,509 citations	43973 48 h-index	31759 101 g-index
175 all docs	175 docs citations	175 times ranked	13185 citing authors

#	Article	IF	Citations
1	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	6.3	1,625
2	Diabetes and cognitive dysfunction. Lancet, The, 2012, 379, 2291-2299.	6.3	722
3	Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes and Endocrinology,the, 2017, 5, 377-390.	5.5	588
4	Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010. JAMA - Journal of the American Medical Association, 2015, 313, 37.	3.8	454
5	Synaptic Glutamate Release by Ventromedial Hypothalamic Neurons Is Part of the Neurocircuitry that Prevents Hypoglycemia. Cell Metabolism, 2007, 5, 383-393.	7.2	358
6	Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiology of Learning and Memory, 2010, 93, 546-553.	1.0	319
7	Frequency of Thyroid Dysfunction in Diabetic Patients: Value of Annual Screening. Diabetic Medicine, 1995, 12, 622-627.	1.2	312
8	Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes and Endocrinology,the, 2019, 7, 385-396.	5.5	298
9	Cognitive Ability and Brain Structure in Type 1 Diabetes: Relation to Microangiopathy and Preceding Severe Hypoglycemia. Diabetes, 2003, 52, 149-156.	0.3	270
10	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology,the, 2021, 9, 82-93.	5.5	251
11	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 864-876.	5.5	244
12	Influence of an Early-Onset Age of Type 1 Diabetes on Cerebral Structure and Cognitive Function. Diabetes Care, 2005, 28, 1431-1437.	4.3	208
13	Serotonin 2C Receptor Agonists Improve Type 2 Diabetes via Melanocortin-4 Receptor Signaling Pathways. Cell Metabolism, 2007, 6, 398-405.	7.2	200
14	Susceptibility of Nrf2-Null Mice to Steatohepatitis and Cirrhosis upon Consumption of a High-Fat Diet Is Associated with Oxidative Stress, Perturbation of the Unfolded Protein Response, and Disturbance in the Expression of Metabolic Enzymes but Not with Insulin Resistance. Molecular and Cellular Biology, 2014, 34, 3305-3320.	1.1	187
15	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 2018, 41, 2552-2559.	4.3	177
16	Hypoglycemia in Type 1 Diabetes. Diabetes, 2010, 59, 2333-2339.	0.3	161
17	Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis AreÂAmeliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2). Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 367-398.	2.3	154
18	Key Role for AMP-Activated Protein Kinase in the Ventromedial Hypothalamus in Regulating Counterregulatory Hormone Responses to Acute Hypoglycemia. Diabetes, 2008, 57, 444-450.	0.3	152

#	Article	IF	Citations
19	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 834-844.	5.5	149
20	Hypothalamic ATP-sensitive K + Channels Play a Key Role in Sensing Hypoglycemia and Triggering Counterregulatory Epinephrine and Glucagon Responses. Diabetes, 2004, 53, 2542-2551.	0.3	145
21	Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure. Circulation, 2020, 142, 1713-1724.	1.6	144
22	Potential Role for AMP-Activated Protein Kinase in Hypoglycemia Sensing in the Ventromedial Hypothalamus. Diabetes, 2004, 53, 1953-1958.	0.3	142
23	A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. European Heart Journal, 2020, 41, 3421-3432.	1.0	138
24	Medium-Chain Fatty Acids Improve Cognitive Function in Intensively Treated Type 1 Diabetic Patients and Support In Vitro Synaptic Transmission During Acute Hypoglycemia. Diabetes, 2009, 58, 1237-1244.	0.3	128
25	Perceived symptoms of hypoglycaemia in elderly Type 2 diabetic patients treated with insulin. , 1998, 15, 398-401.		121
26	Blockade of GABAA Receptors in the Ventromedial Hypothalamus Further Stimulates Glucagon and Sympathoadrenal but Not the Hypothalamo-Pituitary-Adrenal Response to Hypoglycemia. Diabetes, 2006, 55, 1080-1087.	0.3	107
27	Activation of AMP-Activated Protein Kinase Within the Ventromedial Hypothalamus Amplifies Counterregulatory Hormone Responses in Rats With Defective Counterregulation. Diabetes, 2006, 55, 1755-1760.	0.3	107
28	Activation of ATP-Sensitive K+ Channels in the Ventromedial Hypothalamus Amplifies Counterregulatory Hormone Responses to Hypoglycemia in Normal and Recurrently Hypoglycemic Rats. Diabetes, 2005, 54, 3169-3174.	0.3	103
29	Glucose concentrations of less than 3.0Âmmol/l (54Âmg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes. Diabetologia, 2017, 60, 3-6.	2.9	99
30	Ventromedial Hypothalamic Nitric Oxide Production Is Necessary for Hypoglycemia Detection and Counterregulation. Diabetes, 2010, 59, 519-528.	0.3	95
31	Increased GABAergic Tone in the Ventromedial Hypothalamus Contributes to Suppression of Counterregulatory Reponses After Antecedent Hypoglycemia. Diabetes, 2008, 57, 1363-1370.	0.3	93
32	Visual information processing during controlled hypoglycaemia in humans. Brain, 1996, 119, 1277-1287.	3.7	92
33	Cognitive and Neural Hippocampal Effects of Long-Term Moderate Recurrent Hypoglycemia. Diabetes, 2006, 55, 1088-1095.	0.3	92
34	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes Care, 2018, 41, 341-347.	4.3	92
35	Chronic Activation of Î³2 AMPK Induces Obesity and Reduces Î² Cell Function. Cell Metabolism, 2016, 23, 821-836.	7.2	87
36	Update in the CNS Response to Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1-8.	1.8	83

#	Article	IF	Citations
37	Corticotrophin-releasing factor receptors within the ventromedial hypothalamus regulate hypoglycemia- induced hormonal counterregulation. Journal of Clinical Investigation, 2006, 116, 1723-1730.	3.9	81
38	Influence of Insulin in the Ventromedial Hypothalamus on Pancreatic Glucagon Secretion In Vivo. Diabetes, 2010, 59, 1521-1527.	0.3	80
39	Effect of acute hypoglycemia on visual information processing in adults with type 1 diabetes mellitus. Physiology and Behavior, 1998, 64, 653-660.	1.0	76
40	Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia, 2016, 59, 2106-2113.	2.9	71
41	SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia, 2018, 61, 2126-2133.	2.9	68
42	Symptoms of Hypoglycemia in Children With IDDM. Diabetes Care, 1995, 18, 858-861.	4.3	63
43	Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. BMC Nephrology, 2017, 18, 163.	0.8	63
44	The Medial Amygdalar Nucleus: A Novel Glucose-Sensing Region That Modulates the Counterregulatory Response to Hypoglycemia. Diabetes, 2010, 59, 2646-2652.	0.3	60
45	The mechanisms that underlie glucose sensing during hypoglycaemia in diabetes. Diabetic Medicine, 2008, 25, 513-522.	1.2	58
46	Mouse hypothalamic GT1-7 cells demonstrate AMPK-dependent intrinsic glucose-sensing behaviour. Diabetologia, 2012, 55, 2432-2444.	2.9	57
47	Amputation-free survival in 17,353 people at high risk for foot ulceration in diabetes: a national observational study. Diabetologia, 2018, 61, 2590-2597.	2.9	55
48	Appraisal of Mood and Personality During Hypoglycaemia in Human Subjects. Physiology and Behavior, 1999, 67, 27-33.	1.0	53
49	The physiology and pathophysiology of the neural control of the counterregulatory response. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 302, R215-R223.	0.9	52
50	Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1187-1199.	1.8	51
51	Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nature Medicine, 2022, 28, 982-988.	15.2	48
52	Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. Diabetes Therapy, 2018, 9, 1347-1358.	1.2	47
53	Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis. Diabetic Medicine, 2019, 36, 718-725.	1.2	46
54	Glycaemic control trends in people with type 1 diabetes in Scotland 2004â€“2016. Diabetologia, 2019, 62, 1375-1384.	2.9	45

#	Article	IF	Citations
55	Hypoglycaemia, the most feared complication of insulin therapy. DiabÃ¨te & MÃ©tabolisme, 1994, 20, 503-12.	0.3	43
56	Type 2 diabetes, socioeconomic status and life expectancy in Scotland (2012â€“2014): a population-based observational study. Diabetologia, 2018, 61, 108-116.	2.9	42
57	AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E1076-E1083.	1.8	41
58	Hypothalamic AMP-activated protein kinase activation with AICAR amplifies counterregulatory responses to hypoglycemia in a rodent model of type 1 diabetes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2009, 296, R1702-R1708.	0.9	41
59	Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycaemic control, mortality and cardiovascular outcomes: a retrospective cohort study. BMJ Open, 2016, 6, e010836.	0.8	41
60	Potential role of nonâ€insulin adjunct therapy in Typeâ€ƒ1 diabetes. Diabetic Medicine, 2013, 30, 179-188.	1.2	39
61	Renal and Cardiovascular Effects of sodiumâ€“glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ Open, 2017, 7, e018097.	0.8	38
62	Glucose Sensing During Hypoglycemia: Lessons From the Lab. Diabetes Care, 2009, 32, 1357-1363.	4.3	37
63	Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia, 2020, 63, 473-485.	2.9	37
64	Impaired hypoglycaemia awareness in type 1 diabetes: lessons from the lab. Diabetologia, 2018, 61, 743-750.	2.9	36
65	Foot Ulcer and Risk of Lower Limb Amputation or Death in People With Diabetes: A National Population-Based Retrospective Cohort Study. Diabetes Care, 2022, 45, 83-91.	4.3	36
66	Effects of acute hypoglycaemia on auditory information processing in adults with Type I diabetes. Diabetologia, 2003, 46, 97-105.	2.9	35
67	Antecedent Hypercortisolemia Is Not Primarily Responsible for Generating Hypoglycemia-Associated Autonomic Failure. Diabetes, 2006, 55, 1121-1126.	0.3	35
68	Nrf2-Mediated Neuroprotection Against Recurrent Hypoglycemia Is Insufficient to Prevent Cognitive Impairment in a Rodent Model of Type 1 Diabetes. Diabetes, 2016, 65, 3151-3160.	0.3	34
69	Auditory information processing during acute insulin-induced hypoglycaemia in non-diabetic human subjects. Neuropsychologia, 1997, 35, 1547-1553.	0.7	33
70	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia, 2019, 62, 621-632.	2.9	33
71	Consequences of recurrent hypoglycaemia on brain function in diabetes. Diabetologia, 2021, 64, 971-977.	2.9	32
72	Type 1 corticotropin-releasing factor receptors in the ventromedial hypothalamus promote hypoglycemia-induced hormonal counterregulation. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E705-E712.	1.8	30

#	Article	IF	Citations
73	Bace1-dependent amyloid processing regulates hypothalamic leptin sensitivity in obese mice. Scientific Reports, 2018, 8, 55.	1.6	29
74	Visual information processing and intelligence. Intelligence, 1997, 24, 461-479.	1.6	28
75	Advancing Therapy in Suboptimally Controlled Basal Insulinâ€“Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. Diabetes Care, 2021, 44, 2361-2370.	4.3	28
76	Loss of O-GlcNAcase catalytic activity leads to defects in mouse embryogenesis. Journal of Biological Chemistry, 2021, 296, 100439.	1.6	28
77	Efficacy and safety of cotadutide, a dual glucagonâ€like peptideâ€1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 1360-1369.	2.2	28
78	Anger State During Acute Insulin-Induced Hypoglycaemia. Physiology and Behavior, 1999, 67, 35-39.	1.0	27
79	Reducing the burden of hypoglycaemia in people with diabetes through increased understanding: design of the Hypoglycaemia REdefining SOLutions for better liVEs (Hypoâ€RESOLVE) project. Diabetic Medicine, 2020, 37, 1066-1073.	1.2	27
80	Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland. Diabetologia, 2015, 58, 716-725.	2.9	26
81	Implementation of Basalâ€“Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics, 2019, 21, 273-285.	2.4	26
82	Hypothalamic Fkbp51 is induced by fasting, and elevated hypothalamic expression promotes obese phenotypes. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E987-E991.	1.8	25
83	Long-term, intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin resistance: A model for weight gain with intensive insulin therapy. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E131-E138.	1.8	25
84	Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. BMC Cardiovascular Disorders, 2017, 17, 229.	0.7	25
85	<scp>AMP</scp>â€activated protein kinase (<scp>AMPK</scp>) activator <scp>A</scp>â€769662 increases intracellular calcium and <scp>ATP</scp> release from astrocytes in an <scp>AMPK</scp>â€independent manner. Diabetes, Obesity and Metabolism, 2017, 19, 997-1005.	2.2	23
86	Symptomatic and physiological responses to hypoglycaemia induced by human soluble insulin and the analogue Lispro human insulin. , 1997, 14, 929-936.		22
87	5'AMP-activated protein kinase ? deficiency enhances stress-induced apoptosis in BHK and PC12 cells. Journal of Cellular and Molecular Medicine, 2007, 11, 286-298.	1.6	22
88	CD44 contributes to hyaluronan-mediated insulin resistance in skeletal muscle of high-fat-fed C57BL/6 mice. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E973-E983.	1.8	22
89	Hypoglycaemic symptoms reported by children with Type 1 diabetes mellitus and by their parents. , 1998, 15, 836-843.		20
90	High-Intensity Exercise as a Dishabituating Stimulus Restores Counterregulatory Responses in Recurrently Hypoglycemic Rodents. Diabetes, 2017, 66, 1696-1702.	0.3	20

#	Article	IF	Citations
91	Diazoxide Improves Hormonal Counterregulatory Responses to Acute Hypoglycemia in Long-standing Type 1 Diabetes. Diabetes, 2015, 64, 2234-2241.	0.3	19
92	Incident ischaemic stroke and Type 2 diabetes: trends in incidence and case fatality in Scotland 2004â€“2013. Diabetic Medicine, 2018, 35, 99-106.	1.2	19
93	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. Diabetologia, 2021, 64, 1320-1331.	2.9	19
94	Advancing therapy with <scp>iGlarLixi</scp> versus premix BIAsp 30 in basal insulinâ€treated type 2 diabetes: Design and baseline characteristics of the <scp>SoliMix</scp> randomized controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 1221-1231.	2.2	19
95	Dominantly inherited syndrome comprising partially absent eye muscles, hydrocephaly, skeletal abnormalities, and a distinctive facial phenotype. American Journal of Medical Genetics Part A, 1991, 40, 417-420.	2.4	18
96	Radix astragali (Huangqi) as a Treatment for Defective Hypoglycemia Counterregulation in Diabetes. The American Journal of Chinese Medicine, 2010, 38, 1027-1038.	1.5	18
97	AMPK modulates glucose-sensing in insulin-secreting cells by altered phosphotransfer to KATP channels. Journal of Bioenergetics and Biomembranes, 2013, 45, 229-241.	1.0	18
98	Loss of CRMP2 O-GlcNAcylation leads to reduced novel object recognition performance in mice. Open Biology, 2019, 9, 190192.	1.5	17
99	Inhibition of NFAT Signaling Restores Microvascular Endothelial Function in Diabetic Mice. Diabetes, 2020, 69, 424-435.	0.3	17
100	The Scylla and Charybdis of glucose control in childhood type 1 diabetes?. Pediatric Diabetes, 2015, 16, 235-241.	1.2	16
101	Clinical approaches to treat impaired awareness of hypoglycaemia. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110002.	1.4	16
102	Effects of recurrent antecedent hypoglycaemia and chronic hyperglycaemia on brainstem extra-cellular glucose concentrations during acute hypoglycaemia in conscious diabetic BB rats. Diabetologia, 2003, 46, 1658-1661.	2.9	15
103	Amplified Hormonal Counterregulatory Responses to Hypoglycemia in Rats After Systemic Delivery of a SUR-1â€“Selective K+ Channel Opener?. Diabetes, 2008, 57, 3327-3334.	0.3	15
104	Investigating the Relationship Between Type 2 Diabetes and Dementia Using Electronic Medical Records in the GoDARTS Bioresource. Diabetes Care, 2019, 42, 1973-1980.	4.3	14
105	Glycaemic benefit of iGlarLixi in insulinâ€naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLanâ€O randomized trial. Diabetes, Obesity and Metabolism, 2019, 21, 1967-1972.	2.2	14
106	Socioâ€economic status and mortality in people with type 1 diabetes in Scotland 2006â€“2015: a retrospective cohort study. Diabetic Medicine, 2020, 37, 2081-2088.	1.2	14
107	Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study. Diabetes Therapy, 2020, 11, 2629-2645.	1.2	14
108	Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. ESC Heart Failure, 2020, 7, 1168-1177.	1.4	14

#	Article	IF	Citations
109	Adipocyte integrin-linked kinase plays a key role in the development of diet-induced adipose insulin resistance in male mice. Molecular Metabolism, 2021, 49, 101197.	3.0	14
110	Symptoms reported during experimental hypoglycaemia: effect of method of induction of hypoglycaemia and of diabetesper se. Diabetic Medicine, 2003, 20, 507-509.	1.2	13
111	Testing the accelerator hypothesis: a new approach to type 1 diabetes prevention (<scp>adAPT</scp> 1). Diabetes, Obesity and Metabolism, 2016, 18, 3-5.	2.2	13
112	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiologyâ€“Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodiumâ€“Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQq0 0 0 rgBT /Overlock 10	4.3	13
113	A randomised controlled study of high intensity exercise as a dishabituating stimulus to improve hypoglycaemia awareness in people with type 1 diabetes: a proof-of-concept study. Diabetologia, 2020, 63, 853-863.	2.9	13
114	Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS application. BMJ Open, 2022, 12, e051651.	0.8	13
115	The suitability of patient-reported outcome measures used to assess the impact of hypoglycaemia on quality of life in people with diabetes: a systematic review using COSMIN methods. Diabetologia, 2021, 64, 1213-1225.	2.9	12
116	Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. Diabetologia, 2022, 65, 159-172.	2.9	12
117	Real-time Continuous Glucose Monitoring During a Hyperinsulinemic-Hypoglycemic Clamp Significantly Underestimates the Degree of Hypoglycemia. Diabetes Care, 2020, 43, e142-e143.	4.3	11
118	Experimental Models of Impaired Hypoglycaemia-Associated Counter-Regulation. Trends in Endocrinology and Metabolism, 2020, 31, 691-703.	3.1	11
119	Hypoâ€METRICS: Hypoglycaemiaâ€”MEasurement, ThResholds and ImpaCtSâ€”A multiâ€country clinical study to define the optimal threshold and duration of sensorâ€detected hypoglycaemia that impact the experience of hypoglycaemia, quality of life and health economic outcomes: The study protocol. Diabetic Medicine, 2022, 39, .	1.2	11
120	Oleate induces K ATP channel-dependent hyperpolarization in mouse hypothalamic glucose-excited neurons without altering cellular energy charge. Neuroscience, 2017, 346, 29-42.	1.1	9
121	RD Lawrence Lecture 2015 Old habits are hard to break: lessons from the study of hypoglycaemia. Diabetic Medicine, 2017, 34, 148-155.	1.2	9
122	In-vivo correlations between skin metabolic oscillations and vasomotion in wild-type mice and in a model of oxidative stress. Scientific Reports, 2019, 9, 186.	1.6	9
123	Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes. JACC: Cardiovascular Imaging, 2021, 14, 503-504.	2.3	9
124	Cost-Effectiveness of iGlarLixi Versus iDegLira in TypeÂ2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy. Diabetes Therapy, 2021, 12, 3231-3241.	1.2	9
125	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. Diabetes Care, 2021, 44, 2010-2017.	4.3	8
126	Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK. Diabetes Therapy, 2021, 12, 3217-3230.	1.2	8

#	Article	IF	Citations
127	An Estimate of Lifetime Cognitive Change and Its Relationship with Diabetes Health in Older Adults with Type 1 Diabetes: Preliminary Results. Behavioural Neurology, 2010, 23, 165-167.	1.1	7
128	Saxagliptin coâ€therapy in Câ€peptide negative Type 1 diabetes does not improve counterâ€regulatory responses to hypoglycaemia. Diabetic Medicine, 2016, 33, 1283-1290.	1.2	7
129	Hyperinsulinaemicâ€“hypoglycaemic glucose clamps in human research: a systematic review of the literature. Diabetologia, 2021, 64, 727-736.	2.9	7
130	Effect of pancreatic transplantation on counterregulatory hormonal responses to hypoglycaemia. Acta Diabetologica, 1999, 36, 11-20.	1.2	6
131	The Response to Hypoglycemia: A Role for the Opioid System?. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3357-3359.	1.8	6
132	Time trends in deaths before age 50Âyears in people with type 1 diabetes: a nationwide analysis from Scotland 2004â€“2017. Diabetologia, 2020, 63, 1626-1636.	2.9	6
133	3. Cerebral Adaptation to Recurrent Hypoglycemia. Translational Endocrinology & Metabolism, 2012, , 89-114.	0.2	6
134	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. Diabetologia, 2021, 64, 1309-1319.	2.9	5
135	The impact of hypoglycaemia on quality of life among adults with type 1 diabetes: Results from â€œYourSAY: Hypoglycaemiaâ€• Journal of Diabetes and Its Complications, 2023, 37, 108232.	1.2	5
136	Chronic exposure to KATP channel openers results in attenuated glucose sensing in hypothalamic GT1-7 neurons. Neuropharmacology, 2016, 111, 212-222.	2.0	4
137	Cold-induced dishabituation in rodents exposed to recurrent hypoglycaemia. Diabetologia, 2021, 64, 1436-1441.	2.9	4
138	Continuous hypothalamic KATP activation blunts glucose counter-regulation in vivo in rats and suppresses KATP conductance in vitro. Diabetologia, 2013, 56, 2088-2092.	2.9	3
139	Highâ€intensity training as a novel treatment for impaired awareness of hypoglycaemia in type 1 diabetes [HIT4HYPOS]: Protocol for a randomized parallelâ€group study. Endocrinology, Diabetes and Metabolism, 2021, 4, e00166.	1.0	3
140	Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK. Diabetes Therapy, 2022, , .	1.2	3
141	Reducing Glut2 throughout the body does not result in cognitive behaviour differences in aged male mice. BMC Research Notes, 2020, 13, 438.	0.6	2
142	113-OR: ADA Presidents' Select Abstract: Dishabituation with High Intensity Exercise Improves Epinephrine Response and Symptomatic Awareness to Hypoglycemia in People with Type 1 Diabetes and Impaired Awareness of Hypoglycemia. Diabetes, 2019, 68, .	0.3	2
143	Central deficiency of IL-6Ra in mice impairs glucose-stimulated insulin secretion. Molecular Metabolism, 2022, 61, 101488.	3.0	2
144	Hypoglycaemia: Exercise for the Brain?. Journal of Neuroendocrinology, 2012, 24, 1365-1366.	1.2	0

#	Article	IF	Citations
145	An interesting case of new-onset ketosis-prone diabetes in a Scottish teaching hospital. British Journal of Diabetes and Vascular Disease, 2013, 13, 265-268.	0.6	0
146	The genetic association of the transcription factor NPAT with glycemic response to metformin involves regulation of fuel selection. PLoS ONE, 2021, 16, e0253533.	1.1	0
147	Nrf2 mediated protection against hypoglycaemia induced cognitive deficits in type 1 diabetes. Endocrine Abstracts, 0, , .	0.0	0
148	960-P: Characteristics of U.S. Patients with Type 2 Diabetes Prescribed GLP-1RA+SGLT2i in Combination during 2018. Diabetes, 2020, 69, 960-P.	0.3	0
149	Therapieintensivierung bei mit basalunterstÃ¼tzter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Subanalyse der SoliMix-Studie bei Teilnehmern in Europa. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
150	Therapieintensivierung bei mit basalunterstÃ¼tzter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: NÃchtliche HypoglykÃmien in der SoliMix-Studie. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
151	Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstÃ¼tzter oraler Therapie (BOT): Bessere klinische Ergebnisse mit iGlarLixi vs. BIAsp 30 in der SoliMix-Studie. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
152	Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstÃ¼tzter oraler Therapie (BOT): HypoglykÃmien als Funktion des HbA1c in der SoliMix-Studie. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0